Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
IXHL vs LWAY vs JJSF vs CMPS vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
Packaged Foods
Packaged Foods
Medical - Care Facilities
Biotechnology
IXHL vs LWAY vs JJSF vs CMPS vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Packaged Foods | Packaged Foods | Medical - Care Facilities | Biotechnology |
| Market Cap | $165M | $391M | $1.44B | $902M | $2.04B |
| Revenue (TTM) | $104K | $212M | $1.55B | $0.00 | $0.00 |
| Net Income (TTM) | $-62M | $14M | $58M | $-288M | $-238M |
| Gross Margin | 100.0% | 27.4% | 30.5% | — | — |
| Operating Margin | -451.1% | 7.6% | 5.4% | — | — |
| Forward P/E | — | 20.7x | 17.5x | — | — |
| Total Debt | $258K | $360K | $164M | $21M | $0.00 |
| Cash & Equiv. | $15M | $6M | $106M | $150M | $258M |
IXHL vs LWAY vs JJSF vs CMPS vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Incannex Healthcare… (IXHL) | 100 | 1.7 | -98.3% |
| Lifeway Foods, Inc. (LWAY) | 100 | 355.1 | +255.1% |
| J&J Snack Foods Cor… (JJSF) | 100 | 48.8 | -51.2% |
| COMPASS Pathways plc (CMPS) | 100 | 72.8 | -27.2% |
| Mind Medicine (Mind… (MNMD) | 100 | 113.6 | +13.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IXHL vs LWAY vs JJSF vs CMPS vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IXHL ranks third and is worth considering specifically for growth.
- 378.7% revenue growth vs MNMD's -96.9%
LWAY is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 13.7%, EPS growth 50.8%, 3Y rev CAGR 14.5%
- 167.1% 10Y total return vs MNMD's 5.1%
- Lower volatility, beta 0.72, Low D/E 0.4%, current ratio 2.23x
- 6.5% margin vs IXHL's -600.6%
JJSF carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 21 yrs, beta 0.15, yield 4.1%
- PEG 0.62 vs LWAY's 0.62
- Beta 0.15, yield 4.1%, current ratio 2.72x
- Better valuation composite
Among these 5 stocks, CMPS doesn't own a clear edge in any measured category.
MNMD is the clearest fit if your priority is momentum.
- +214.0% vs JJSF's -30.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 378.7% revenue growth vs MNMD's -96.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 6.5% margin vs IXHL's -600.6% | |
| Stability / Safety | Beta 0.15 vs MNMD's 1.68 | |
| Dividends | 4.1% yield; 21-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +214.0% vs JJSF's -30.6% | |
| Efficiency (ROA) | 13.6% ROA vs IXHL's -305.4%, ROIC 17.8% vs -8.2% |
IXHL vs LWAY vs JJSF vs CMPS vs MNMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
IXHL vs LWAY vs JJSF vs CMPS vs MNMD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LWAY leads in 2 of 6 categories
JJSF leads 2 • MNMD leads 1 • IXHL leads 0 • CMPS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LWAY leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JJSF and MNMD operate at a comparable scale, with $1.6B and $0 in trailing revenue. LWAY is the more profitable business, keeping 6.5% of every revenue dollar as net income compared to IXHL's -600.6%. On growth, IXHL holds the edge at +2.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $103,965 | $212M | $1.6B | $0 | $0 |
| EBITDAEarnings before interest/tax | -$47M | $20M | $160M | -$179M | -$191M |
| Net IncomeAfter-tax profit | -$62M | $14M | $58M | -$288M | -$238M |
| Free Cash FlowCash after capex | -$15M | $0 | $90M | -$157M | -$174M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +27.4% | +30.5% | — | — |
| Operating MarginEBIT ÷ Revenue | -451.1% | +7.6% | +5.4% | — | — |
| Net MarginNet income ÷ Revenue | -600.6% | +6.5% | +3.7% | — | — |
| FCF MarginFCF ÷ Revenue | -141.6% | -7.8% | +5.8% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.7% | +18.0% | -3.2% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +47.4% | +15.8% | -64.6% | -58.7% | -163.0% |
Valuation Metrics
JJSF leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 22.5x trailing earnings, JJSF trades at a 22% valuation discount to LWAY's 28.8x P/E. Adjusting for growth (PEG ratio), JJSF offers better value at 0.79x vs LWAY's 0.86x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $165M | $391M | $1.4B | $902M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $151M | $385M | $1.5B | $774M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.53x | 28.81x | 22.53x | -3.05x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.68x | 17.53x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 0.86x | 0.79x | — | — |
| EV / EBITDAEnterprise value multiple | — | 19.12x | 9.50x | — | — |
| Price / SalesMarket cap ÷ Revenue | 1923.03x | 1.84x | 0.91x | — | — |
| Price / BookPrice ÷ Book value/share | 12.35x | 4.64x | 1.53x | — | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — | 17.50x | — | — |
Profitability & Efficiency
LWAY leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LWAY delivers a 17.2% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-5 for IXHL. LWAY carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JJSF's 0.17x. On the Piotroski fundamental quality scale (0–9), IXHL scores 4/9 vs CMPS's 2/9, reflecting mixed financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.7% | +17.2% | +6.2% | -3.4% | -102.5% |
| ROA (TTM)Return on assets | -3.1% | +13.6% | +4.3% | -106.8% | -70.7% |
| ROICReturn on invested capital | -8.2% | +17.8% | +6.1% | — | -3.9% |
| ROCEReturn on capital employed | -191.2% | +19.7% | +7.0% | -2.5% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.00x | 0.17x | — | — |
| Net DebtTotal debt minus cash | -$15M | -$5M | $58M | -$129M | -$258M |
| Cash & Equiv.Liquid assets | $15M | $6M | $106M | $150M | $258M |
| Total DebtShort + long-term debt | $258,000 | $360,000 | $164M | $21M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -160.97x | 256.99x | 50.00x | -52.40x | -21.81x |
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LWAY five years ago would be worth $52,703 today (with dividends reinvested), compared to $108 for IXHL. Over the past 12 months, MNMD leads with a +214.0% total return vs JJSF's -30.6%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs IXHL's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -59.0% | +12.5% | -15.5% | +43.4% | +51.7% |
| 1-Year ReturnPast 12 months | +32.2% | +6.1% | -30.6% | +151.1% | +214.0% |
| 3-Year ReturnCumulative with dividends | -91.7% | +327.3% | -48.1% | +11.0% | +510.3% |
| 5-Year ReturnCumulative with dividends | -98.9% | +427.0% | -46.4% | -72.4% | -57.9% |
| 10-Year ReturnCumulative with dividends | -98.9% | +167.1% | -5.2% | -67.6% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -56.4% | +62.3% | -19.6% | +3.5% | +82.7% |
Risk & Volatility
Evenly matched — JJSF and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
JJSF is the less volatile stock with a 0.15 beta — it tends to amplify market swings less than MNMD's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs IXHL's 9.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.65x | 0.72x | 0.15x | 1.33x | 1.68x |
| 52-Week HighHighest price in past year | $49.80 | $34.20 | $129.24 | $10.21 | $21.09 |
| 52-Week LowLowest price in past year | $0.34 | $17.31 | $73.75 | $2.25 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +9.6% | +75.0% | +58.6% | +92.0% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 67.0 | 64.8 | 38.2 | 68.1 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 590K | 63K | 254K | 3.7M | 792K |
Analyst Outlook
JJSF leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: LWAY as "Buy", JJSF as "Buy", CMPS as "Buy", MNMD as "Buy". Consensus price targets imply 89.9% upside for CMPS (target: $18) vs -3.3% for MNMD (target: $20). JJSF is the only dividend payer here at 4.10% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $35.00 | — | $17.83 | $20.00 |
| # AnalystsCovering analysts | — | 6 | 11 | 13 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — | +4.1% | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | 21 | — | — |
| Dividend / ShareAnnual DPS | — | — | $3.11 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.6% | 0.0% | 0.0% |
LWAY leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JJSF leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
IXHL vs LWAY vs JJSF vs CMPS vs MNMD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IXHL or LWAY or JJSF or CMPS or MNMD a better buy right now?
For growth investors, Incannex Healthcare Limited (IXHL) is the stronger pick with 378.
7% revenue growth year-over-year, versus 0. 5% for J&J Snack Foods Corp. (JJSF). J&J Snack Foods Corp. (JJSF) offers the better valuation at 22. 5x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Lifeway Foods, Inc. (LWAY) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IXHL or LWAY or JJSF or CMPS or MNMD?
On trailing P/E, J&J Snack Foods Corp.
(JJSF) is the cheapest at 22. 5x versus Lifeway Foods, Inc. at 28. 8x. On forward P/E, J&J Snack Foods Corp. is actually cheaper at 17. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: J&J Snack Foods Corp. wins at 0. 62x versus Lifeway Foods, Inc. 's 0. 62x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — IXHL or LWAY or JJSF or CMPS or MNMD?
Over the past 5 years, Lifeway Foods, Inc.
(LWAY) delivered a total return of +427. 0%, compared to -98. 9% for Incannex Healthcare Limited (IXHL). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus IXHL's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IXHL or LWAY or JJSF or CMPS or MNMD?
By beta (market sensitivity over 5 years), J&J Snack Foods Corp.
(JJSF) is the lower-risk stock at 0. 15β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 1002% more volatile than JJSF relative to the S&P 500. On balance sheet safety, Lifeway Foods, Inc. (LWAY) carries a lower debt/equity ratio of 0% versus 17% for J&J Snack Foods Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — IXHL or LWAY or JJSF or CMPS or MNMD?
By revenue growth (latest reported year), Incannex Healthcare Limited (IXHL) is pulling ahead at 378.
7% versus 0. 5% for J&J Snack Foods Corp. (JJSF). On earnings-per-share growth, the picture is similar: Lifeway Foods, Inc. grew EPS 50. 8% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, LWAY leads at 14. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IXHL or LWAY or JJSF or CMPS or MNMD?
Lifeway Foods, Inc.
(LWAY) is the more profitable company, earning 6. 5% net margin versus -545. 2% for Incannex Healthcare Limited — meaning it keeps 6. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LWAY leads at 7. 6% versus -276. 6% for IXHL. At the gross margin level — before operating expenses — IXHL leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IXHL or LWAY or JJSF or CMPS or MNMD more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, J&J Snack Foods Corp. (JJSF) is the more undervalued stock at a PEG of 0. 62x versus Lifeway Foods, Inc. 's 0. 62x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, J&J Snack Foods Corp. (JJSF) trades at 17. 5x forward P/E versus 20. 7x for Lifeway Foods, Inc. — 3. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CMPS: 89. 9% to $17. 83.
08Which pays a better dividend — IXHL or LWAY or JJSF or CMPS or MNMD?
In this comparison, JJSF (4.
1% yield) pays a dividend. IXHL, LWAY, CMPS, MNMD do not pay a meaningful dividend and should not be held primarily for income.
09Is IXHL or LWAY or JJSF or CMPS or MNMD better for a retirement portfolio?
For long-horizon retirement investors, J&J Snack Foods Corp.
(JJSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 15), 4. 1% yield). Incannex Healthcare Limited (IXHL) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JJSF: -5. 2%, IXHL: -98. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IXHL and LWAY and JJSF and CMPS and MNMD?
These companies operate in different sectors (IXHL (Healthcare) and LWAY (Consumer Defensive) and JJSF (Consumer Defensive) and CMPS (Healthcare) and MNMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IXHL is a small-cap high-growth stock; LWAY is a small-cap quality compounder stock; JJSF is a small-cap income-oriented stock; CMPS is a small-cap quality compounder stock; MNMD is a small-cap quality compounder stock. JJSF pays a dividend while IXHL, LWAY, CMPS, MNMD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.